Publicacións en colaboración con investigadores/as de Centro de Investigación Biomédica en Red de Cáncer (12)

2024

  1. Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer

    Frontiers in Oncology, Vol. 14

2023

  1. Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial

    Therapeutic Advances in Medical Oncology, Vol. 15

  2. Somatic mutations in tumor and plasma of locoregional recurrent and/or metastatic head and neck cancer using a next-generation sequencing panel: A preliminary study

    Cancer Medicine, Vol. 12, Núm. 6, pp. 6615-6622

2022

  1. BlaDimiR: A Urine-based miRNA Score for Accurate Bladder Cancer Diagnosis and Follow-up

    European Urology

  2. Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

    BMC Cancer, Vol. 22, Núm. 1

2021

  1. Aberrant integration of Hepatitis B virus DNA promotes major restructuring of human hepatocellular carcinoma genome architecture

    Nature Communications, Vol. 12, Núm. 1

2019

  1. CDK4/6 inhibitor as a novel therapeutic approach for advanced bladder cancer independently of RB1 status

    Clinical Cancer Research, Vol. 25, Núm. 1, pp. 390-402

  2. Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet

    Frontiers in Genetics, Vol. 10

2018

  1. The Ras-related gene ERAS is involved in human and murine breast cancer

    Scientific Reports, Vol. 8, Núm. 1

  2. Thyroid Hormone Receptors Regulate the Expression of microRNAs with Key Roles in Skin Homeostasis

    Thyroid, Vol. 28, Núm. 7, pp. 921-932

2017

  1. BMP4 induces M2 macrophage polarization and favors tumor progression in bladder cancer

    Clinical Cancer Research, Vol. 23, Núm. 23, pp. 7388-7399

  2. Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma

    Oncotarget, Vol. 8, Núm. 18, pp. 30410-30421